The vector of anti-CLL-1 chimeric antigen receptor (CAR) is based on the FcεRI receptor scaffold and constructed for the engineering of T cells to target human CLL-1. The T cells are genetically modified through transduction with a lentiviral vector expressing an alpha chain comprising a scFv of anti-CLL-1 antibody linked to FcεR1γ-SP and FcεR1γ-TM-IC, a beta chain comprising FcεR1γ-ΔITAM linked to 4-1BB (CD137) signaling domain, a gamma chain comprising FcεR1γ-SP-ΔITAM linked to CD3ζ signaling domain. And the vector product was designed for the treatment of acute lymphoblastic leukemia.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
Call us at:
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE